Autopsy report · NCT00503776

Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia

“funding became unavailable”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 6 months after it had already started.
• Ran for about 2 years 7 months before it stopped.
• 41 participants enrolled.
• Results were posted on the registry 3 years 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Vanderbilt-Ingram Cancer Center

Sponsor type

University, hospital or other

Conditions

Dysphagia; Head and Neck Cancer; Mucositis; Xerostomia

Interventions

exercise intervention; amifostine trihydrate; therapeutic dietary intervention

Participants

41

Sites

1

Countries

United States

Trials that died the same way

• Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma
  “Funding has become unavailable” (96% match in meaning)
• PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer
  “Funding unavailable” (95% match in meaning)
• A Cardiac Registry to Evaluate and Manage the hsTnI Categorical CVD Risk in Subjects Undergoing Preventive Health Checks (PHC).
  “Unavailable funding” (94% match in meaning)
• Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer
  “Funding was not available” (91% match in meaning)
• Evaluation and Adverse Event Surveillance for Initial Implementation of ShangRing Circumcision in Mozambique
  “Funding no longer available” (90% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.